Status:
COMPLETED
A Comparison of Bupropion SR and Placebo for Smoking Cessation
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
US Department of Veterans Affairs
Conditions:
Tobacco Use Disorder
Eligibility:
FEMALE
18-64 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine whether the adjunctive use of bupropion SR in the context of a psychoeducational program modified for people with schizophrenia might improve the likelihood of ...
Detailed Description
After obtaining consent, patients will enter a two week stabilization phase followed by a 14 week treatment phase. The treatment phase begins with a 9 session group therapy led by clinic nurses traine...
Eligibility Criteria
Inclusion
- Inclusion Criteria are:
- DSM-IV diagnosis of Schizophrenia or schizoaffective disorder
- Age: 18-64
- Regular half pack a day smokers
- Score of at least 4 on the Nicotine Dependency Test
Exclusion
- Exclusion Criteria are:
- <!-- -->
- Seizure disorders, other Neurologic illnesses, or a family history of seizures
- A medical condition that could manifest psychiatrically
- Currently experiencing a depressive episode
- Active substance abuse
- Currently receiving bupropion
- Pregnant women
- Children (\<18 years of age)
- Two consecutive sodium levels of 130 mmol/L or less
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00176449
Start Date
April 1 2001
End Date
December 1 2005
Last Update
August 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maryland Psychiatric REsearch Center
Catonsville, Maryland, United States, 21228